U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H25NO
Molecular Weight 259.3871
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPERISONE

SMILES

CCc1ccc(cc1)C(=O)C(C)CN2CCCCC2

InChI

InChIKey=SQUNAWUMZGQQJD-UHFFFAOYSA-N
InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C17H25NO
Molecular Weight 259.3871
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/18836866

Eperisone is an antispasmodic drug approved in Japan for the treatment of of diseases characterized by muscle stiffness and pain. It is believed that eperisone exerts its effect through inhibition of sodium channels. The drug is still being marketed in Asia under the name Myonal (Square Pharmaceuticals).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
Palliative
MYONAL

Approved Use

Improvement of myotonic conditions caused by Neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain; Spastic paralysis caused by the following diseases: Cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, post-surgical sequelae (including cerebrospinal tumor), sequelae of trauma (spinal injury and head injury), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy (SMON) and other encephalomyelopathies.
PubMed

PubMed

TitleDatePubMed
Determination of eperisone in human plasma by liquid chromatography-ESI-tandem mass spectrometry.
2007 Sep
Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study.
2008 Jul-Aug
Patents

Sample Use Guides

150 mg of eperisone hydrochloride daily in three divided doses after meals
Route of Administration: Oral
In Vitro Use Guide
Eperisone (25–200 uM) depressed the ventral root potential of isolated hemisected spinal cord of 6-day-old rats.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:10:02 UTC 2021
Edited
by admin
on Sat Jun 26 03:10:02 UTC 2021
Record UNII
2M2P0551D3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EPERISONE
INN   MI   WHO-DD  
INN  
Official Name English
EPERISONE [WHO-DD]
Common Name English
EPERISONE [MI]
Common Name English
1-(4-ETHYLPHENYL)-2-METHYL-3-(1-PIPERIDINYL)-1-PROPANONE
Systematic Name English
EPERISONE [INN]
Common Name English
4'-ETHYL-2-METHYL-3-PIPERIDINOPROPIOPHENONE
Systematic Name English
Classification Tree Code System Code
WHO-ATC M03BX09
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
WHO-VATC QM03BX09
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
NCI_THESAURUS C66880
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
Code System Code Type Description
EPA CompTox
64840-90-0
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
WIKIPEDIA
EPERISONE
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
CAS
64840-90-0
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
MERCK INDEX
M4931
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY Merck Index
EVMPD
SUB06560MIG
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
DRUG CENTRAL
1022
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
PUBCHEM
3236
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
FDA UNII
2M2P0551D3
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
INN
5153
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
MESH
C030848
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
ChEMBL
CHEMBL1902981
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
NCI_THESAURUS
C83692
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
DRUG BANK
DB08992
Created by admin on Sat Jun 26 03:10:02 UTC 2021 , Edited by admin on Sat Jun 26 03:10:02 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY